<DOC>
	<DOCNO>NCT02302495</DOCNO>
	<brief_summary>IFM 2012-03 protocol Phase 2 multicenter nonrandomized open elderly patient multiple myeloma diagnosis . Study primary objective first step determine Maximum tolerate dose ( MTD ) Carfilzomib Weekly base definition Dose-limiting toxicity ( DLTs ) second step expand cohort , determine VGPR ( Very Good Partial Response ) + CR ( Complete Response ) rate Carfilzomib Weekly MTD combination Melphalan Prednisone end 9 induction cycle .</brief_summary>
	<brief_title>Study Carfilzomib Weekly Plus Melphalan Prednisone Untreated Symptomatic Elderly Multiple Myeloma</brief_title>
	<detailed_description>Overall design . This study Multicenter , Open-label , Phase 2 study Carfilzomib Weekly +MP Untreated Elderly MM . Eligible patient must symptomatic , untreated MM measurable disease . There dose escalation part study MTD remain determined carfilzomib weekly give 4 infusion ( day 1 , 8 , 15 , 22 ) 35-days cycle . This study thus comprise 2 part . Step 1 . To determine MTD Carfilzomib Weekly base definition DLTs - ( N=6 patient per cohort , maximum 5 cohort carfilzomib weekly +MP ) The patient include three cohort 36 mg/m² , 45 mg/m² , 56 mg/m² 70mg/m² Carfilzomib Weekly give 4 infusion ( day 1 , 8 , 15 , 22 ) +MP give day 1 4 35-days cycle . Carfilzomib administer dose 36mg/m² first cohort 20 mg/m² dose administer Day 1 Cycle 1 36 mg/m² subsequent dos . If dose-limiting toxicity ( DLTs ) occur few equal 2 patient , next cohort 6 patient ( cohort 2 ) open patient receive dose 20/45 mg/m² . If DLTs occur few equal 2 patient cohort 2 , third cohort 6 patient receive dose 20/56 mg/m² 20 mg/m² dose administer Day 1 Cycle 1 56 mg/m² subsequent dos . If DLTs occur few equal 2 patient cohort 3 , fourth five cohort 6 patient receive dose 20/70 mg/m² 20 mg/m² dose administer Day 1 Cycle 1 70 mg/m² subsequent dos . If time cycle 1 dose cohort , &gt; 2 subject experience drug-related DLT , MTD exceed , additional enrolment within cohort cease , dose escalation stop . The MTD define dose level DLT observe &gt; 33 % ( i.e . &gt; 2 6 ) subject cohort . The following defined DLTs : - Any hematologic toxicity grade 4 intensity prevent administration 2 4 carfilzomib dos first treatment cycle - Grade ≥ 3 febrile neutropenia - Grade ≥ 3 gastrointestinal toxicity - Any grade ≥ 3 nonhematologic toxicity consider related CMP principal investigator . - Grade ≥ 3 peripheral neuropathy persist 3 week discontinuation study drug . Exceptions : 1. grade 4 thrombocytopenia without bleed last ≤ 7 day 2. grade 4 neutropenia last ≤ 7 day 3. grade ≥ 3 nausea/ vomit patient receive adequate antiemetic prophylaxis Adverse event ( AEs ) grade accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE , version 4.0 ) . MTD determination base occurrence DLTs first induction treatment cycle . Step 2 . Expanded Cohort ( N=50 patient ; Carfilzomib weekly MTD +MP ) After identification MTD , plan dose cohort expand include total 50 patient treat MTD carfilzomib weekly step 2 study . A full treatment course step 1 , see `` dose regimen '' .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>able understand voluntarily sign informed consent form able adhere study visit schedule protocol requirement . age ≥ 65 year . life expectancy &gt; 6 months.Patients must Symptomatic Measurable previously Untreated MM measurable disease define follow : quantifiable monoclonal Mcomponent value serum and/or urine eastern Cooperative Oncology Group performance status score ≤2 dequate bone marrow function , document within 72 hour without transfusion 5 day prior first intake investigational product growth factor support Adequate organ function subject affiliate appropriate social security system . male subject must : Understand potential teratogenic , genotoxic risk Melphalan engage sexual activity pregnant female female childbearing potential . understand potential genotoxic risk Carfilzomib engage sexual activity pregnant female female childbearing potential . practice complete abstinence understand need agree use condom sexual contact pregnant female female childbearing potential throughout entire duration study treatment , dose interruption least 3 month end treatment discontinuation CMP , even undergone successful vasectomy . pregnancy positive pregnancy test occur partner male study patient study participation , investigator must notify immediately . agree donate semen sperm study drug therapy least 3 month end treatment discontinuation CMP . uncontrolled medical condition comorbidity might interfere subject 's participation . know positive HIV active infectious hepatitis , type B C. patient terminal renal failure require dialysis clearance creatinine &lt; 30 ml/min . prior history malignancy , multiple myeloma , unless patient free disease ≥ 5 year . prior local irradiation within two week first dose evidence central nervous system ( CNS ) involvement . unable take corticotherapy study entry ongoing adverse event medical history &gt; grade 2 severity person protect legal regime ( guardianship , trusteeship ) .Alkeran 's ( Melphalan ) contraindication : Hypersensitivity Melphalan constituent . patient heart failure class 3 4 accord NYHA criterion , patient past history myocardial infarction within last 6 month control cardiac conduction abnormality . patient leave ventricular ejection fraction equal 45 % ( LVEF ≤ 45 % )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Carfilzomib weekly</keyword>
	<keyword>Melphalan Prednisone</keyword>
</DOC>